The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
No Micky. Not stated as fact by HEMO that will start in 2023. Only 'expected to'. Not sure why folk getting hung up on this. IMHO if we dont see IND application submitted by 1Q24 then we would have cause for concern, not before.
RNS: ''Prevail InfoWorks, Inc. to act as Contract Research Organization (CRO) for upcoming Phase I clinical study, expected to commence in 2023''
Im not thinking the same as you Micky - I dont agree with your personal insults of Dr S. I think he is trying to do remarkable work within a tight budget. I have been here for a few years now with an investment that any FA would tell me to reduce. But since HEMO severed the arrangement with Mint all of the news has been very positive.
If HEMO is not valued minimum £100m through 1Q24 your frustration may be justified. GL
I wonder if we will be advised how many volunteers are part of Phase 1 trials and what the programme will be for the announcement of results. Obviously it would be good to know how things are trending prior to conclusion. Thoughts appreciated.
I think they will be Pump!
When I reflect on this company I can barely contain my excitement. I only see good things from the arrangement with Prevail. I know the more hard nosed may disagree - but as JHFH points out you either consider this to be make believe or not, that really is the bottom line.
I haven't been disappointed by the share price over the last few months as Im fortunate it has allowed me to average down to accumulate a significant holding. The current mcap really is nothing when compared to peers (better than me have given plenty of examples of the transactions in this sector). I do see the risk of further funds being required through trials but as Charles Archer articulates - there are numerous possibilities.
It was poignant to hear the death of Anna Chancellors daughter Poppy this week at the young age of 36. She was diagnosed just earlier this year - another reminder of how aggressive this leukaemia is.
What ever issues one may have with Dr S, as a CEO, Im in no doubt he is doing is utmost to get HEMO CATR T to trials asap, and ultimately alleviate the suffering this cancer brings.
GLA